PYC Therapeutics: Clinical Trials

6 trials sponsored by PYC Therapeutics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 2 recruiting. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Active not recruiting 2, Completed 2, Recruiting 2
Phase 22Active not recruiting 1, Recruiting 1

Follow PYC Therapeutics: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
Phase 1 / Phase 2RecruitingPYC Therapeutics242025-09-302026-06-29
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration
Phase 1 / Phase 2Active not recruitingPYC Therapeutics172025-06-012026-05-29
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
PYC-003 - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 1RecruitingPYC Therapeutics1662025-04-072026-07-27
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy
Phase 1Active not recruitingPYC Therapeutics182024-10-312026-09-17
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration
Phase 1CompletedPYC Therapeutics62024-06-132026-05-29
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
VP-001 - Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy
Phase 1CompletedPYC Therapeutics172023-04-202026-05-29

Conditions studied

Retinal Dystrophies (3)  ·  Optic Atrophies, Hereditary (2)  ·  Optic Atrophy, Autosomal Dominant (2)  ·  Retinal Degeneration (2)  ·  Retinal Diseases (2)  ·  Retinitis Pigmentosa 11 (2)  ·  Eye Diseases (1)  ·  Eye Diseases, Hereditary (1)  ·  Polycystic Kidney, Autosomal Dominant (1)

Countries

Australia (3)  ·  United States (3)  ·  New Zealand (2)  ·  Hong Kong (1)

Top investigators

Aishwarya Kundu (1)  ·  Sreenivasu Mudumba (1)